drugset / Trial / NCT05586477

Diphenhydramine and Sweating

NCT05586477

Phase 4 Completed 20 enrolled Lakehead University
RandomizedCrossoverSingle-blindTreatment

Summary

In 2012, it was estimated that nearly 1 in 4 Canadians suffer from allergic rhinitis. To add, 78% of individuals working in predisposing environments are predicted to develop occupational rhinitis. Currently, the most popular treatment for rhinitis is antihistamine medication such as diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®. Due it its anticholinergic effects, diphenhydramine has been suggested to impair the whole body sweating response during heat stress, potentially leaving consumers at an increased risk of heat-related illness. This randomized control trial approved by Health Canada will investigate whether ingesting extra strength diphenhydramine (50mg) will alter whole-body sweat losses during 60 minutes of exercise.

Timeline

Start
2022-11-21
Primary completion
2023-06-23
Completion
2023-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Diphenhydramine Unknown 50 mg Oral

Indications